Approved HCV Drugs
Approved HCV Drugs
Studies Show High Cure Rates for Interferon-free Hepatitis C Treatment
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 12 August 2014 00:00
- Written by HIVandHepatitis.com
An all-oral combination of daclatasvir (Daklinza) plus asunaprevir led to sustained virological response (SVR) in 82%-90% of treatment-naive and previously treated people with hepatitis C virus genotype 1b, while a regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured 92%-94% of hepatitis C patients with or without cirrhosis, according to findings from a pair of clinical trials reported in the July 28 advance online edition of The Lancet.
DDW2014: Coverage of Digestive Disease Week 2014
- Details
- Category: HBV Treatment
- Published on Saturday, 31 May 2014 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2014 Digestive Disease Week annual meeting (DDW 2014) in Chicago, May 3-6, 2014.
Hepatitis C
New Hepatitis C Treatments Highlighted at Digestive Disease Week
Some Negative Predictive Factors Do Not Impair Response to Faldaprevir
AbbVie Interferon-free Regimen Cures More than 90% of Hepatitis C Patients
Sustained Response to Interferon Is Durable in Children with Hepatitis C
HIV/HCV Coinfection
Some Negative Predictive Factors Do Not Impair Response to Faldaprevir
Hepatitis B
Outcomes in HBV/HCV Coinfected People Depend on Which Virus Dominates
Some Hepatitis B Patients Can Stop Antiviral Treatment Without Relapse
Complications and Related Conditions
Rifaximin May Be Beneficial for People with Advanced Liver Cirrhosis
Drinking More Coffee Is Associated with Less Liver Fibrosis
Telaprevir Triple Therapy Shows Activity Against HCV Genotype 4
- Details
- Category: HCV Treatment
- Published on Wednesday, 04 September 2013 00:00
- Written by Liz Highleyman
The HCV protease inhibitor telaprevir (Incivek or Incivo) in combination with pegylated interferon and ribavirin reduced viral levels by more than 4 log in people with genotype 4 hepatitis C in a short Phase 2a study, researchers reported in the September 15, 2013 Journal of Infectious Diseases.
IDWeek 2013: Older People Respond Equally Well to Telaprevir Triple Therapy for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 15 October 2013 00:00
- Written by Liz Highleyman
Interferon-based therapy with telaprevir (Incivek or Incivo) produced a similar cure rate with no notable increase in side effects or treatment discontinuation for genotype 1 chronic hepatitis C patients over age 60, Japanese researchers reported at the second IDWeek conference held recently in San Francisco.
EASL 2013: 12 Weeks of Telaprevir Triple Therapy Adequate for Some Hep C Patients
- Details
- Category: HCV Treatment
- Published on Thursday, 13 June 2013 00:00
- Written by Liz Highleyman
Nearly 90% of genotype 1 chronic hepatitis C patients with favorable response factors including the IL28B CC gene variant achieved a cure with just 12 weeks of telaprevir (Incicek or Incivo) plus pegylated interferon/ribavirin, rising to 97% for those treated for 24 weeks, researchers reported at the recent EASL International Liver Congress (EASL 2013) in Amsterdam.
More Articles...
- DDW 2013: Prior Non-responders Can Achieve Good SVR Rates with Boceprevir Triple Therapy
- DDW 2013: Drug Interactions May Compromise Response to Boceprevir and Telaprevir
- DDW 2013: Viral Breakthrough May Occur during Interferon/Ribavirin 'Tail' of HCV Triple Therapy
- Coverage of Digestive Disease Week 2013
Web Design and Development by